Ziftomenib
Brand names: Komzifti · Active ingredient: Ziftomenib
In short: KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options .
What is Ziftomenib used for?
KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options .
⚠ Boxed warning (FDA's strongest warning)
Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement
[see Dosage and Administration (2.5), Warnings and Precautions (5.1), and Adverse Reactions (6.1)]
.
Ziftomenib dosage
Select patients for the treatment of relapsed or refractory AML with KOMZIFTI based on the presence of an NPM1 mutation .
An FDA-approved test for the detection of NPM1 mutations is not currently available.
The recommended dosage of KOMZIFTI is 600 mg taken orally once daily until disease progression or unacceptable toxicity. Do not start KOMZIFTI until the white blood cell (WBC) count is reduced to less than 25 x 10⁹/L. For patients without confirmed disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response.
Administer KOMZIFTI once daily on an empty stomach (at least 1 hour before or 2 hours after a meal) .
Administer KOMZIFTI orally at about the same time each day.
Swallow capsules whole. Do not open, break, or chew the capsules.
If a dose of KOMZIFTI is missed or not taken at the usual time, administer the dose as soon as possible on the same day and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.
Avoid concomitant use of proton pump inhibitors (PPIs) with KOMZIFTI.
Avoid concomitant use of a histamine-2 (H2) receptor antagonist or a locally acting antacid with KOMZIFTI . If concomitant use cannot be avoided:
Take KOMZIFTI 2 hours before or 10 hours after administration of an H2 receptor antagonist.
Take KOMZIFTI 2 hours before or 2 hours after administration of a locally acting antacid.
Manage any abnormalities promptly .
Interrupt or reduce dose for adverse reactions as per Table 1 and Table 2.
Adverse Reaction
a | Recommended Action
a Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
b Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening.
c See Table 2 for the reduced dose levels.
Differentiation syndrome
| If differentiation syndrome is suspected, interrupt KOMZIFTI.
Administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days and provide supportive care.
Resume KOMZIFTI at the same dose level when signs and symptoms improve and are Grade ≤ 2b.
Noninfectious leukocytosis (e.g., sudden or significant white blood cell (WBC) increase, including WBC doubling within the first 2 weeks of administration or an absolute increase of 10 x 109/L) | Evaluate for differentiation syndrome.
Initiate treatment with hydroxyurea, as per standard institutional practices, and leukapheresis if clinically indicated.
Taper hydroxyurea only after leukocytosis improves or resolves.
Interrupt KOMZIFTI if leukocytosis is not controlled with hydroxyurea within 48 hours. If interrupted, resume KOMZIFTI at the same dose level once WBC counts are controlled. …
How to take Ziftomenib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Differentiation Syndrome
Advise patients of the risk of developing differentiation syndrome as early as 3 days after the start of therapy and during treatment. Instruct patients to immediately report any symptoms suggestive of differentiation syndrome, such as fever, joint or bone pain, dizziness, shortness of breath or difficulty breathing, cough, chest pain, rapid weight gain, rash, decreased urinary output, or swelling in the hands, feet, ankles, or legs, to their healthcare provider for further evaluation .
Prolonged QT Interval
Advise patients to consult their healthcare provider immediately if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia. Advise patients with a history of hypokalemia or hypomagnesemia of the importance of monitoring their electrolytes .
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider of a known or suspected pregnancy . …
Warnings & precautions
Do not take this medicine if: None.
KOMZIFTI can cause fatal or life-threatening differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells. Symptoms of differentiation syndrome, including those seen in patients treated with KOMZIFTI, may include fever, hypoxia, joint pain, hypotension, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, acute kidney injury, and rashes.
In the clinical trial, differentiation syndrome occurred in 29 (26%) of 112 patients with relapsed or refractory AML with an NPM1 mutation who were treated with KOMZIFTI at the recommended dosage. Differentiation syndrome was Grade 3 in 13% and fatal in two patients. In broader evaluation of all patients with any genetic form of AML treated with KOMZIFTI monotherapy in clinical trials, differentiation syndrome occurred in 25% of patients. Four fatal cases of differentiation syndrome occurred out of 39 patients with KMT2A-rearranged AML treated with KOMZIFTI. KOMZIFTI is not approved for use in patients with KMT2A-rearranged AML.
In the 112 patients with an NPM1 mutation, differentiation syndrome was observed with and without concomitant hyperleukocytosis, in as early as 3 days and up to 46 days after KOMZIFTI initiation. The median time to onset was 15 days. Two patients experienced more than one differentiation syndrome event. Treatment was interrupted and resumed in 15 (13%) patients, while it was permanently discontinued in 2 (2%) patients .
Prior to starting treatment with KOMZIFTI, reduce the WBC counts to less than 25 x 10⁹/L. If differentiation syndrome is suspected, interrupt KOMZIFTI, initiate oral or intravenous corticosteroids (e.g., dexamethasone 10 mg every 12 hours) for a minimum of 3 days with hemodynamic and laboratory monitoring. …
Ziftomenib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Differentiation Syndrome
QTc Interval Prolongation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Relapsed or Refractory AML with an
NPM1
Mutation
The safety of KOMZIFTI for the treatment of patients with relapsed or refractory AML with an NPM1 mutation was evaluated in KO-MEN-001 . Patients received KOMZIFTI 600 mg once daily (n=112). The median duration of exposure to KOMZIFTI was 2.2 months (range 0.1 to 21.5 months).
Fatal adverse reactions occurred in 4 (4%) patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death. Serious adverse reactions were reported in 79% of patients who received KOMZIFTI. Serious adverse reactions occurring in ≥ 5% of patients included infection without an identified pathogen (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%).
Dosage interruption of KOMZIFTI due to an adverse reaction occurred in 54% of patients. …
Drug interactions
Strong or Moderate CYP3A4 Inhibitors
Monitor patients more frequently for KOMZIFTI-associated adverse reactions.
Ziftomenib is primarily metabolized by CYP3A. Concomitant use of KOMZIFTI with strong or moderate CYP3A4 inhibitors increases ziftomenib exposure , which may increase the risk of adverse reactions such as QT prolongation.
Strong or Moderate CYP3A4 Inducers
Avoid concomitant use of KOMZIFTI with strong or moderate CYP3A4 inducers.
Ziftomenib is primarily metabolized by CYP3A. Concomitant use of KOMZIFTI with strong or moderate CYP3A4 inducers may decrease ziftomenib exposure , which may reduce the efficacy of KOMZIFTI.
Gastric Acid Reducing Agents
Concomitant administration of ziftomenib with proton pump inhibitors (PPIs) decreases ziftomenib exposure , which may reduce the efficacy of KOMZIFTI.
Avoid concomitant use of KOMZIFTI with PPIs.
Avoid concomitant use of KOMZIFTI with H2 receptor antagonists (H2RAs) or locally acting antacids. If concomitant use cannot be avoided, modify KOMZIFTI administration time .
Drugs that Prolong the QT Interval
Avoid concomitant use of KOMZIFTI with other product(s) with a known potential to prolong the QTc interval. …
About this medicine
KOMZIFTI contains ziftomenib, a menin inhibitor.
The chemical name is (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile.
The chemical structure is:
The molecular formula is C33H42F3N9O2S2 and the molecular weight is 717.88 g/mol.
Ziftomenib is a white to off-white powder and is highly soluble in aqueous solution at pH 1.2 and practically insoluble at pH ≥4.
KOMZIFTI (ziftomenib) is available as a 200 mg capsule for oral administration.
Each KOMZIFTI capsule contains 200 mg ziftomenib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, and sodium lauryl sulfate. The capsule shells, imprinted with black ink, contain the following inactive ingredients: hypromellose and titanium dioxide.
How it works: Ziftomenib is a menin inhibitor that blocks the interaction of menin and lysine [K]-specific methyltransferase 2A (KMT2A). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b650f696-3391-4274-8b55-a5f5e9d04769. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate